Pete England

Chief Commercial Officer at ViaLase

Pete England has a diverse work experience in the healthcare industry. Pete began their career as a Medical Sales Representative at Alcon Laboratories, Inc. in 2005 and later served as a Regional Training Manager before becoming a District Manager. As a District Manager, they provided leadership to a high-performing sales team and won the District Sales Manager of the Year award multiple times. In 2012, Pete transitioned to the role of Senior Brand Manager at Alcon, where they managed a $360M franchise of glaucoma pharmaceutical therapies and exceeded brand share and revenue objectives. Pete then joined Smith & Nephew as the Director of US Market Strategy, Advanced Wound Management. At Smith & Nephew, Pete led a team in developing a disease-centric business model to gain ownership positions in key wound care markets. Pete later returned to Alcon as the Global Product Director for Surgical Glaucoma, where they developed a Global Launch Readiness Process and standardized advisory board activity. After their time at Alcon, Pete held positions at 2e Creative, Fishawack Health, and Sight Sciences, Inc. In these roles, they led strategic partnerships and headed the eye care division. Currently, Pete is the Vice President of Global Marketing at ViaLase, Inc. and also serves on the Board of Directors for the Angelman Syndrome Foundation.

From 1996 to 2000, Pete England attended Texas Christian University. No details regarding the degree or field of study pursued were provided.

Location

Fort Worth, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


ViaLase

2 followers

ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. The company's system focuses on the development of micron-resolution OCT image-guided femtosecond laser technology to create micron-sized customized drainage channels through the trabecular meshwork that connects the anterior chamber to theSchlemm's canal without surgically opening or penetrating the eye, enabling medical professionals to improve glaucoma management with its efficient non-invasive treatment.ViaLase was incorporated in 2019 and is headquartered in Corona Del Mar, California.